The ASPEN randomized trial showed that novel brensocatib cut the annualized rate of pulmonary exacerbations by around 20% compared with placebo. Brensocatib is a DPP-1 inhibitor that works by reducing ...
MORRISTOWN, N.J.--(BUSINESS WIRE)--Alitair Pharmaceuticals, Inc., today announced that the Office of Orphan Products Development (OOPD) of the Food and Drug Administration (FDA) has granted orphan ...
Edmond Pharma announced that the FDA has granted Orphan Drug status to erdosteine, a molecule being developed for the treatment of bronchiectasis. Erdosteine is a thiol, with muco-modulatory, ...
Please provide your email address to receive an email when new articles are posted on . The mean number of pulmonary exacerbations did not significantly differ among those receiving vs. not receiving ...
"Non-Cystic Fibrosis Bronchiectasis Clinical Trials"Key Non-Cystic Fibrosis Bronchiectasis Companies are Zambon SpA, Insmed Incorporated, NovaBiotics, Haisco Pharmaceutical Group, Armata ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results